In Silico Analysis of miRNA in Type 2 Diabetes Mellitus and Colorectal Cancer: Molecular Connections and Biomarker Potential
DOI:
https://doi.org/10.25170/juhr.v4i2.7497Keywords:
Type 2 diabetes mellitus, Colorectal cancer, in silico, hsa miR-182-3pAbstract
Introduction: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia caused by insulin resistance and impaired insulin secretion, affecting 537 million adults worldwide in 2021 and projected to reach 783 million by 2045. T2DM increases the risk of malignancies, particularly colorectal cancer (CRC). MicroRNAs (miRNAs), small non-coding RNAs regulating gene expression, have emerged as molecular links between T2DM and CRC through their roles in proliferation, apoptosis, metabolism, and insulin signaling. Shared pathways, including PI3K/AKT/mTOR and IGF-1 signaling, support common pathogenic mechanisms. Due to their stability and disease-specific expression, miRNAs represent promising biomarkers. This study employs an in silico bioinformatics approach to identify shared dysregulated miRNAs, predict their target genes, analyze relevant molecular pathways, and evaluate their regulatory roles connecting T2DM with CRC development.
Methods: This study employed an in silico approach using miRNA expression data from GEO datasets (GSE262614, GSE185845, GSE115513, GSE156732), analyzed with R under the criteria |Log2FC| > 1 and p < 0.05. Differentially expressed miRNAs from each dataset were compared using a Venn diagram to identify consistently dysregulated miRNAs. Target gene prediction was conducted using miRTargetLink 2.0 and miRWalk, followed by validation with mRNA datasets GSE25724 and GSE44076. Pathway enrichment analyses were performed using GO and KEGG through ShinyGO and Enrichr
Results: Analysis revealed that hsa-miR-182-3p was the only miRNA consistently experiencing upregulation in both T2DM and colorectal cancer. From hsa miR-182-3p a total of 9 validated target genes were identified, and most of them are involved in MAPK, mTOR, cell cycle, and insulin signaling pathways which are key pathways implicated in both diseases.
Conclusion: This study indicates that hsa-miR-182-3p may serve as a molecular mediator linking the pathophysiological mechanisms of T2DM, such as insulin resistance and hyperinsulinemia, with colorectal cancer tumorigenesis, and may hold potential as a biomarker.
References
1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022; 183: 109119.
2. Sari I. Effect of Diabetes Exercise on Reduction of Blood Glucose Levels in Patients with Type II Diabetes Mellitus. Heal Tadulako J (Jurnal Kesehat Tadulako) 2025; 11: 620–627.
3. de Kort S, Masclee AAM, Sanduleanu S, et al. Higher risk of colorectal cancer in patients with newly diagnosed diabetes mellitus before the age of colorectal cancer screening initiation. Sci Rep 2017; 7: 46527.
4. Lawler T, Walts ZL, Steinwandel M, et al. Type 2 Diabetes and Colorectal Cancer Risk. JAMA Netw Open 2023; 6: e2343333.
5. Guraya SY. Association of type 2 diabetes mellitus and the risk of colorectal cancer: A meta-analysis and systematic review. World J Gastroenterol 2015; 21: 6026–6031.
6. Roshandel G, Ghasemi-Kebria F, Malekzadeh R. Colorectal Cancer: Epidemiology, Risk Factors, and Prevention. Cancers (Basel) 2024; 16: 1530.
7. Abdel Mageed SS, Doghish AS, Ismail A, et al. The role of miRNAs in insulin resistance and diabetic macrovascular complications – A review. Int J Biol Macromol 2023; 230: 123189.
8. Natalicchio A, Montagnani M, Gallo M, et al. MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM)/Italian Association of Medical Diabetologists (AMD)/Italian Society of Diabetology (SID)/Italian Society of Endocri. ESMO Open 2023; 8: 101573.
9. Asiri A, Al Qarni A, Bakillah A. The Interlinking Metabolic Association between Type 2 Diabetes Mellitus and Cancer: Molecular Mechanisms and Therapeutic Insights. Diagnostics 2024; 14: 2132.
10. Helal HG, Rashed MH, Abdullah OA, et al. MicroRNAs (−146a, −21 and −34a) are diagnostic and prognostic biomarkers for diabetic retinopathy. Biomed J 2021; 44: S242–S251.
11. Kong YW, Ferland-McCollough D, Jackson TJ, et al. microRNAs in cancer management. Lancet Oncol 2012; 13: e249–e258.
12. Fathi E, Mesbah-Namin S, Farahzadi R. Biomarkers in Medicine: An Overview. Br J Med Med Res; 4. Epub ahead of print 21 December 2013. DOI: 10.9734/BJMMR/2014/6917.
13. Ahmad A, Imran M, Ahsan H. Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases. Pharmaceutics 2023; 15: 1630.
14. Fagoonee S, Menchise V, Delli Castelli D, et al. Emerging Biomarker Potential of Extracellular Vesicle-Enclosed MicroRNAs for Liver Fibrosis Detection. Cells 2025; 14: 1025.
15. Li X, Zhang X, Zhang Q, et al. miR-182 contributes to cell proliferation, invasion and tumor growth in colorectal cancer by targeting DAB2IP. Int J Biochem Cell Biol 2019; 111: 27–36.
16. Zhang T, Li W, Gu M, et al. Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation. Cancer Manag Res 2021; Volume 13: 3539–3550.
17. Sameti P, Tohidast M, Amini M, et al. The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target. Cancer Cell Int 2023; 23: 134.
18. Fleming-de-Moraes CD, Rocha MR, Tessmann JW, et al. Crosstalk between PI3K/Akt and Wnt/β-catenin pathways promote colorectal cancer progression regardless of mutational status. Cancer Biol Ther 2022; 23: 1–13.
19. Mousavikia SN, M. Matin M, Bahreyni Tossi MT, et al. Identification and modulation of a PI3K/AKT/mTOR pathway-targeting microRNA in order to increase colorectal cancer cells radiosensitivity in vitro. BMC Cancer 2025; 25: 1172.
20. Jia L, Luo S, Ren X, et al. miR-182 and miR-135b Mediate the Tumorigenesis and Invasiveness of Colorectal Cancer Cells via Targeting ST6GALNAC2 and PI3K/AKT Pathway. Dig Dis Sci 2017; 62: 3447–3459.
21. Li Y, Zhang H, Li Y, et al. MiR‐182 inhibits the epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met gene. Mol Carcinog 2018; 57: 125–136.
22. Wang X, Xue X, Pang M, et al. Epithelial–mesenchymal plasticity in cancer: signaling pathways and therapeutic targets. MedComm; 5. Epub ahead of print August 2024. DOI: 10.1002/mco2.659.
23. He L, Wang X, Chen X. Unveiling the role of microRNAs in metabolic dysregulation of Gestational Diabetes Mellitus. Reprod Biol 2024; 24: 100924.
24. Zhang D, Li Y, Yao X, et al. miR-182 Regulates Metabolic Homeostasis by Modulating Glucose Utilization in Muscle. Cell Rep 2016; 16: 757–768.
25. Rao J, Chen Y, Huang J, et al. Inhibiting miR-182-3p Alleviates Gestational Diabetes Mellitus by Improving Insulin Resistance in Skeletal Muscle. Balkan Med J 2021; 39: 121–129.
26. Vasu S, Kumano K, Darden CM, et al. MicroRNA Signatures as Future Biomarkers for Diagnosis of Diabetes States. Cells 2019; 8: 1533.
27. Pająk W, Kleinrok J, Pec J, et al. Micro RNA in Colorectal Cancer—Potential Diagnostic and Prognostic Markers—An Updated Review. Int J Mol Sci 2025; 26: 8615.
28. Schwab S, Nonaka T. Circulating miRNAs as liquid biopsy biomarkers for diagnosis in patients with colorectal cancer: a systematic review and meta-analysis. Front Genet; 16. Epub ahead of print 28 July 2025. DOI: 10.3389/fgene.2025.1574586.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Alexander Ryan Wihardja, Ana Lucia Ekowati, Ferbian Milas Siswanto
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
